Dear All, What a wild day … it feels like the flood gates have opened! I am still smiling about the amazing BARDA announcement of 10 further years of funding for an Antibacterial Accelerator! In parallel, six (6!) contractor/job openings have popped onto my radar! Three are with WHO and three are with the recently created
Dear All, Just below my signature you will find the full details on a recently posted WHO consultancy opportunity. It’s an intriguing 6-month project during which you would be responsible for the rollout and implementation of a new WHO Policy Guidance on the Implementation of Integrated Antimicrobial Stewardship Activities. This guidance will be rolled out in
Dear All, Deadline: 15 August 2021: The World Health Organization (WHO) is seeking experts to serve as members of the Advisory Group on the Bacterial Priority Pathogen List (AG BPPL). A “Call for experts” document provides information about the advisory group and the expert profiles being sought for the group. The document also provides information on
Dear All, Just now posted is an excellent opportunity to be a full-time Team Lead at WHO in the AMR group with Peter Beyer. Here’s the link you need: https://careers.who.int/careersection/ex/jobdetail.ftl?job=2100011 In brief, this is a very visible and senior Team Lead role with a top-level job description of “Develops and proposes innovative technical health policies
Dear All, WHO have opened a call for experts to be part of an Advisory Group on their Critically Important Antimicrobial (CIA) List. Background: As discussed in this 12 Oct 2020 newsletter, WHO and FDA’s Center for Veterinary Medicine (CVM) rank antibiotics to determine which can be used in animals vs. those that must preserved for
Dear All, First up today is a very interesting new workshop from FDA on 1-2 Sep entitled “Advancing the Development of Pediatric Therapeutics (ADEPT 7) Complex Innovative Trial Design.” In brief: “The Complex Innovative Trial Design Pilot Meeting Program (CID Program) facilitates and advances the use of complex and innovative trial designs that have the potential
Dear All, Two brief items today: First, a survey on OneHealth research priorities from WHO/FAO/OIE: “The Tripartite collaboration between World Health Organization (WHO), Food and Agricultural Organization of the United Nations (FAO), and World Organization for Animal Health (OIE)) is joining efforts to develop a One Health priority research agenda on antimicrobial resistance (AMR). “This
Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference
Dear All, Quick note today as I am both exhausted and exhilarated by having listened to the all-day FDA Advisory committee on the Pfizer/BioNTech COVID vaccine: There is more to learn (the timelines are unlike anything you’ve ever seen before and include a Phase 1-2-3 trial design!!), but the efficacy is impressive and the risk/benefit
Dear All, WHO have been thinking about the threat of resistant fungi as well as resistant bacteria. An initial discussion by a small working group on approaches to priority fungal pathogens (April 2020, here’s the link to the report) concluded that Candida auris; azole-resistant Candida spp., azole-resistant Aspergillus fumigatus, Cryptococcus neoformans (& C. gattii), Pneumocystis jirovecii, Mucorales, and potentially Histoplasmosis were